# Title XELOX FOR SALIVARY GLAND CANCERS

> **NCT00101075** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00101075
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2007-03
- **Final completion:** 2008-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2017-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101075, "Title XELOX FOR SALIVARY GLAND CANCERS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00101075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*